Semaglutide vs. empagliflozin Overall, 7,899 patients treated with semaglutide and 7,899 treated with empagliflozin were propensity-matched (mean age, 62 years).

A study compared the association of semaglutide vs other antidiabetic medications and other GLP-1RAs, including liraglutide and dulaglutide, with opioid overdose risk in patients with comorbid ...

Patients aged 45 years or older with type 2 diabetes treated from Jan. 1, 2019, to Dec. 31, 2024, with semaglutide, dulaglutide, or empagliflozin were included in the study.